Undisclosed SMOC2 targetting antibodies / Mediar Therap - LARVOL DELTA

Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) (PRNewswire) - "Mediar Therapeutics, Inc...announced a global licensing agreement with Eli Lilly and Company to advance MTX-463 into a Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF)...Following completion of the Phase 2 study, Lilly will have the right to lead all further clinical development and commercialization of the program...Under the terms of the agreement Mediar will receive a combined $99 million, which is inclusive of an upfront payment and near-term milestones. Mediar may receive up to an additional $687 million in potential downstream development and commercialization milestones. Additionally, Mediar is eligible to receive high-single to low-double digit royalty payments and net sales milestones based on potential future product sales...Mediar's third novel fibrosis program, targeting SMOC2, is also advancing with a plan to nominate a clinical candidate in the first half of 2025...Mediar expects to initiate a Phase 2 study in IPF with MTX-463 in 1H-2025."

Licensing / partnership • New molecule • New P2 trial • Fibrosis • Idiopathic Pulmonary Fibrosis